GlaxoSmithKline has announced it will open up anonymised data from clinical trials for further research. Shar Nebhrajani argues that openness can lead to more innovation, and asks: is it time for new models of intellectual property rights?
Dr Denise Goldman, on why promising new treatments fall into a 'valley of death' and how Action on Hearing Loss initiatives - from funding translational research to engaging with industry by providing free consultancy and market intelligence reports, are working to overcome it.
On Monday I attended a very interesting talk by Tim Harford at the Policy Exchange in Westminster. Tim is an economist, he writes for the Financial Times and also has several best sellers in which he boils economics down to its basics. His talk, called Innovating for growth, was about how to stimulate technological innovation, […]
An invention is only patentable if it is believed to be useful in any industry. However, a new judgment by the UK’s Supreme Court has ruled that patents need only contain “plausible” suggestions of uses for the new technology. This will make it easier to patent the products of research in the life sciences and […]
A new report published by BIS comparing the UK against other research-intensive nations highlights the international strength of the UK research community but also warns that it is under threat from underfunding and a decreasing share of the international scientific workforce. The report includes some pretty interesting statistics about research in the UK, comparing what […]